Enanta Pharmaceuticals (ENTA) Share-based Compensation (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Share-based Compensation came in at $24.9 million in Q1 2026, up 431.19% YoY from $4.7 million in Q1 2025, and up 2.93% on a QoQ basis from $24.2 million in Q2 2025.
Enanta Pharmaceuticals (ENTA) Share-based Compensation (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Share-based Compensation data on file, last reported at $24.9 million in Q1 2026.
- Quarterly Share-based Compensation rose 431.19% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (down 41.12% YoY) and the FY2025 annual result came in at $18.8 million, down 39.31% from the prior year.
- Share-based Compensation grew to $24.9 million in Q1 2026, from $24.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $26.5 million in Q3 2024 to a low of $4.7 million in Q1 2025.
- A 5-year average of $11.7 million and a median of $7.1 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation slipped 24.47% — and 2026, when it soared 431.19%.
- Tracing ENTA's Share-based Compensation over 5 years: stood at $7.1 million in 2022, then surged by 245.09% to $24.6 million in 2023, then slumped by 77.0% to $5.7 million in 2024, then surged by 326.99% to $24.2 million in 2025, then gained by 2.93% to $24.9 million in 2026.
- The last three Share-based Compensation figures came in at $24.9 million (Q1 2026), $24.2 million (Q2 2025), and $4.7 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 21.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.61 Mn |
| Jun 30, 2026 | 21.61 Mn |
| Mar 31, 2026 | 24.90 Mn |
| Mar 31, 2026 | 24.90 Mn |
| Jun 30, 2025 | 24.19 Mn |
| Jun 30, 2025 | 24.19 Mn |
| Mar 31, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.69 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | 26.52 Mn |
| Sep 30, 2024 | 26.52 Mn |
| Jun 30, 2024 | 5.42 Mn |
| Jun 30, 2024 | 5.42 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Mar 31, 2024 | 5.56 Mn |
| Sep 30, 2023 | 24.64 Mn |
| Sep 30, 2023 | 24.64 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Jun 30, 2023 | 7.00 Mn |